BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26524858)

  • 1. [Alternative Splicing Detection as Biomarker Candidates for Cancer Diagnosis and Treatment with Establishment of Clinical Biobank in Chiba University].
    Matsushita K; Itoga S; Nishimura M; Furuta K; Nomura F
    Rinsho Byori; 2015 Mar; 63(3):347-60. PubMed ID: 26524858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.
    Matsushita K; Kitamura K; Rahmutulla B; Tanaka N; Ishige T; Satoh M; Hoshino T; Miyagi S; Mori T; Itoga S; Shimada H; Tomonaga T; Kito M; Nakajima-Takagi Y; Kubo S; Nakaseko C; Hatano M; Miki T; Matsuo M; Fukuyo M; Kaneda A; Iwama A; Nomura F
    Oncotarget; 2015 Mar; 6(7):5102-17. PubMed ID: 25671302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Alternative Splicing Detection as a Biomarker for Cancer Diagnosis: A Novel Progressive Mechanism of Acute Lymphoblastic Leukemia with Alternative Splicing as a Biomarker Candidate].
    Kitamura K; Matsushita K; Kobayashi S; Ishige T; Semba T; Kimura A; Kazami T; Ohyama M; Itoga S; Beppu M; Nishimura M; Satoh M; Nomura F
    Rinsho Byori; 2015 Sep; 63(9):1091-102. PubMed ID: 26731899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAP155-mediated splicing of FUSE-binding protein-interacting repressor serves as a molecular switch for c-myc gene expression.
    Matsushita K; Kajiwara T; Tamura M; Satoh M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Yoshimoto R; Ito A; Kubo S; Natsume T; Levens D; Yoshida M; Nomura F
    Mol Cancer Res; 2012 Jun; 10(6):787-99. PubMed ID: 22496461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative splicing of FBP-interacting repressor coordinates c-Myc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for bleomycin-induced DNA damage pathway.
    Rahmutulla B; Matsushita K; Satoh M; Seimiya M; Tsuchida S; Kubo S; Shimada H; Ohtsuka M; Miyazaki M; Nomura F
    Oncotarget; 2014 May; 5(9):2404-17. PubMed ID: 24811221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAP155-mediated c-myc suppressor far-upstream element-binding protein-interacting repressor splicing variants are activated in colon cancer tissues.
    Kajiwara T; Matsushita K; Itoga S; Tamura M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Habara Y; Matsuo M; Nomura F
    Cancer Sci; 2013 Feb; 104(2):149-56. PubMed ID: 23113893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions between SAP155 and FUSE-binding protein-interacting repressor bridges c-Myc and P27Kip1 expression.
    Matsushita K; Tamura M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Levens D; He L; Liu J; Yoshida M; Nomura F
    Mol Cancer Res; 2013 Jul; 11(7):689-98. PubMed ID: 23594796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative splicing of DNA damage response genes and gastrointestinal cancers.
    Rahmutulla B; Matsushita K; Nomura F
    World J Gastroenterol; 2014 Dec; 20(46):17305-13. PubMed ID: 25516641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical application of alternative splicing form of c-myc suppressor FUSE-binding protein-interacting repressor for cancer detection and treatment].
    Matsushita K; Kajiwara T; Itoga S; Satoh M; Sogawa K; Umemura H; Sawai S; Nishimura M; Tamura M; Tanaka N; Shimada H; Tomonaga T; Nomura F
    Rinsho Byori; 2009 Dec; 57(12):1151-8. PubMed ID: 20077813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams.
    Kano M; Matsushita K; Rahmutulla B; Yamada S; Shimada H; Kubo S; Hiwasa T; Matsubara H; Nomura F
    Gene Ther; 2016 Jan; 23(1):50-6. PubMed ID: 26241176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An essential role of alternative splicing of c-myc suppressor FUSE-binding protein-interacting repressor in carcinogenesis.
    Matsushita K; Tomonaga T; Shimada H; Shioya A; Higashi M; Matsubara H; Harigaya K; Nomura F; Libutti D; Levens D; Ochiai T
    Cancer Res; 2006 Feb; 66(3):1409-17. PubMed ID: 16452196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of far upstream element (FUSE) binding protein (FBP)-interacting repressor (FIR) supports growth of hepatocellular carcinoma.
    Malz M; Bovet M; Samarin J; Rabenhorst U; Sticht C; Bissinger M; Roessler S; Bermejo JL; Renner M; Calvisi DF; Singer S; Ganzinger M; Weber A; Gretz N; Zörnig M; Schirmacher P; Breuhahn K
    Hepatology; 2014 Oct; 60(4):1241-50. PubMed ID: 24824848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy.
    Matsushita K; Shimada H; Ueda Y; Inoue M; Hasegawa M; Tomonaga T; Matsubara H; Nomura F
    World J Gastroenterol; 2014 Apr; 20(15):4316-28. PubMed ID: 24764668
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Kimura A; Kitamura K; Ailiken G; Satoh M; Minamoto T; Tanaka N; Nomura F; Matsushita K
    Oncotarget; 2017 Sep; 8(40):67955-67965. PubMed ID: 28978087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-transcriptional regulation of BRG1 by FIRΔexon2 in gastric cancer.
    Ailiken G; Kitamura K; Hoshino T; Satoh M; Tanaka N; Minamoto T; Rahmutulla B; Kobayashi S; Kano M; Tanaka T; Kaneda A; Nomura F; Matsubara H; Matsushita K
    Oncogenesis; 2020 Feb; 9(2):26. PubMed ID: 32071290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The FUSE/FBP/FIR/TFIIH system is a molecular machine programming a pulse of c-myc expression.
    Liu J; Kouzine F; Nie Z; Chung HJ; Elisha-Feil Z; Weber A; Zhao K; Levens D
    EMBO J; 2006 May; 25(10):2119-30. PubMed ID: 16628215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-FIRΔexon2, a splicing variant form of PUF60, autoantibody is detected in the sera of esophageal squamous cell carcinoma.
    Kobayashi S; Hiwasa T; Ishige T; Rahmutulla B; Kano M; Hoshino T; Minamoto T; Shimada H; Nomura F; Matsubara H; Matsushita K
    Cancer Sci; 2019 Jun; 110(6):2004-2013. PubMed ID: 30980774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disturbed alternative splicing of FIR (PUF60) directed cyclin E overexpression in esophageal cancers.
    Ogura Y; Hoshino T; Tanaka N; Ailiken G; Kobayashi S; Kitamura K; Rahmutulla B; Kano M; Murakami K; Akutsu Y; Nomura F; Itoga S; Matsubara H; Matsushita K
    Oncotarget; 2018 May; 9(33):22929-22944. PubMed ID: 29796163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Link of mRNA and rRNA Transcription by PUF60/FIR through TFIIH/P62 as a Novel Therapeutic Target for Cancer.
    Kitamura K; Hoshino T; Okabe A; Fukuyo M; Rahmutulla B; Tanaka N; Kobayashi S; Tanaka T; Shida T; Ueda M; Minamoto T; Matsubara H; Kaneda A; Ishii H; Matsushita K
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy of c-myc suppressor FUSE-binding protein-interacting repressor by Sendai virus delivery prevents tracheal stenosis.
    Mizokami D; Araki K; Tanaka N; Suzuki H; Tomifuji M; Yamashita T; Ueda Y; Shimada H; Matsushita K; Shiotani A
    PLoS One; 2015; 10(1):e0116279. PubMed ID: 25569246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.